➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
McKinsey
Dow
Colorcon
Moodys

Last Updated: October 23, 2021

DrugPatentWatch Database Preview

Claims for Patent: 8,283,380


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,283,380
Title:Methods for treatment of parkinson's disease
Abstract: New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists.
Inventor(s): Fariello; Ruggero (Luino, IT), Cattaneo; Carlo (Milan, IT), Salvati; Patricia (Arese, IT), Benatti; Luca (S. Maurizio al Lambro, IT)
Assignee: Newron Pharmaceuticals S.p.A. (Bresso, IT)
Application Number:10/559,982
Patent Claims: 1. In a method of treating idiopathic Parkinson's disease in a patient receiving a stable dose of levodopa, the improvement comprising: concurrently administering safinamide, or a pharmaceutically acceptable salt thereof, on an oral dosage schedule of about 0.5 mg/kg/day to about 5 mg/kg/day, while maintaining the patient on a stable dose of levodopa.

2. A method of treating idiopathic Parkinson's Disease, comprising: administering a therapeutically effective stable dose of levodopa; and concurrently administering safinamide, or a pharmaceutically acceptable salt thereof, on an oral dosage schedule of about 0.5 mg/kg/day to about 5 mg/kg/day.

3. The method of claim 1 or claim 2, wherein safinamide, or pharmaceutically acceptable salt thereof, is administered on a daily dosage schedule of no more than about 5 mg/kg/day.

4. The method of claim 1 or claim 2, wherein safinamide, or pharmaceutically acceptable salt thereof, is administered on a daily dosage schedule of no more than 200 mg/day.

5. The method of claim 1 or claim 2, wherein safinamide, or pharmaceutically acceptable salt thereof, is administered for at least 12 weeks.

6. The method of claim 1 or claim 2, wherein safinamide, or pharmaceutically acceptable salt thereof, is administered once daily.

7. The method of claim 1 or claim 2, wherein safinamide is administered as the methanesulfonate salt.

8. The method of claim 1 or claim 2, wherein levodopa is administered with a peripheral decarboxylase inhibitor selected from carbidopa and benserazide.

9. The method of claim 1 or claim 2, further comprising administering a catechol-O-methyltransferase inhibitor.

10. The method of claim 9, wherein said catechol-O-methyltransferase inhibitor is tolcapone or entacapone.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Johnson and Johnson
Merck
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.